EA
AMRI

Emerald Acquisition’s Albany Molecular Research Inc AMRI Stock Holding History

Emerald Acquisition’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$3.58M Sell
217,126
-20,328
-9% -$301K 0.01% 1414
2016
Q2 		$3.19M Buy
+237,454
New +$3.46M 0.01% 1603

Other funds holding AMRI

PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Emerald Acquisition's AMRI Position: Q3 2016 in Review

Emerald Acquisition reduced its Albany Molecular Research Inc (AMRI) stake by 8.6% in Q3 2016, selling an estimated $301K and leaving 217,126 shares worth $3.58M. The position accounts for 0.01% of the portfolio, ranked #1414.

Emerald Acquisition first reported a position in AMRI in Q2 2016 and has held it in 2 quarters since. 137 funds tracked by Wall St. Rank hold AMRI as of Q3 2016.

  • Emerald Acquisition held 217,126 shares of Albany Molecular Research Inc worth $3.58M as of Q3 2016.
  • Emerald Acquisition sold 20,328 Albany Molecular Research Inc shares in Q3 2016, an estimated $301K.
  • Albany Molecular Research Inc made up 0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1414 holding.
  • Emerald Acquisition first reported a position in Albany Molecular Research Inc in Q2 2016 and has held it in 2 quarters since.
  • 137 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.